Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luteolin Safety in Prostate Cancer Patients
jRCTs041210142Completed
- Start
- Feb 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of luteolin in prostate cancer (PCa). Primary endpoint: Incidence and severity of adverse events. Started Feb 2022; status: completed.
02
Drugs
luteolin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs041210142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210142.